Issue

Vol. 29 No. 6 (2017): Vol 29 Issue 6

Copyright (c) 2017 AJC

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Buoyant in situ Gels of Meloxicam-b-Cyclodextrin-Triethanolamine Ternary Complex for Oral Delivery; From a Box-Behnken Experimental Design to in vivo Activity Detail

https://doi.org/10.14233/ajchem.2017.20466
Mohammed Jafar
Department of Pharmaceutics, College of Clinical Pharmacy, University of Dammam, P.O. Box 1982, Dammam-31441, Saudi Arabia
Mohammed Salahuddin
Institute for Research and Medical Consultation studies, University of Dammam, P.O. Box 1982, Dammam-31441, Saudi Arabia
Tarek S. Kayed
Department of Basic Sciences and Humanities, College of Engineering, University of Dammam, P.O. Box 1982, Dammam-31441, Saudi Arabia
Niyaz Ahmad
Department of Pharmaceutics, College of Clinical Pharmacy, University of Dammam, P.O. Box 1982, Dammam-31441, Saudi Arabia
Huda A. Al-Eid
Department of Pharmaceutics, College of Clinical Pharmacy, University of Dammam, P.O. Box 1982, Dammam-31441, Saudi Arabia
Abdullah H. Al-Qarros
Department of Pharmaceutics, College of Clinical Pharmacy, University of Dammam, P.O. Box 1982, Dammam-31441, Saudi Arabia

Corresponding Author(s) : Mohammed Jafar

mjomar@uod.edu.sa

Asian Journal of Chemistry, Vol. 29 No. 6 (2017): Vol 29 Issue 6

Abstract

The aim of the present study was to ameliorate the aqueous solubility and dissolution rate of meloxicam by preparing its ternary complex with b-cyclodextrin and triethanolamine and to develop its gastric buoyant in situ gels to improve in vivo anti-inflammatory activity of meloxicam. Meloxicam-b-cyclodextrin-triethanolamine ternary complexes were characterized by FTIR, XRD and SEM techniques. A total of fifteen meloxicam-b-cyclodextrin-triethanolamine ternary complex incorporated buoyant in situ gels were prepared and optimized using a Box-Behnken design. Independent variables (concentrations of gellan gum, calcium carbonate and meloxicam respectively) were optimized in order to achieve the desired responses. The response surface plots and the possible interactions between the independent variables were analyzed using the Design Expert software 10.0.3. (Stat-Ease, Inc, USA). The results showed that the optimized buoyant in situ gels with short floating lag time (0.7 min), low viscosity (210 cps) and high in vitro drug release at 6th hour (92 %) was obtained using an optimized combination of calcium carbonate (0.75 % w/v), gellan gum (0.25 %w/v) and MLX-b-CD-TEA ternary complex (equivalent to 11 mg of meloxicam), respectively. The optimized formulation exhibited significantly high anti-inflammatory activity compared to in situ gel containing pure meloxicam. It was stable for over 3 months. Hence it may be used for the effective oral delivery of meloxicam.

Keywords

Meloxicam Inclusion complex Solubility in situ gel in vivo activity
Jafar, M., Salahuddin, M., Kayed, T. S., Ahmad, N., Al-Eid, H. A., & Al-Qarros, A. H. (2017). Buoyant in situ Gels of Meloxicam-b-Cyclodextrin-Triethanolamine Ternary Complex for Oral Delivery; From a Box-Behnken Experimental Design to in vivo Activity Detail. Asian Journal of Chemistry, 29(6), 1275–1284. https://doi.org/10.14233/ajchem.2017.20466
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. P. Luger, K. Daneck, W. Engel, G. Trummlitz and K. Wagner, Eur. J. Pharm. Sci., 4, 175 (1996); https://doi.org/10.1016/0928-0987(95)00046-1.
  2. J.L. Wallace, Best Pract. Res. Clin. Gastroenterol., 14, 147 (2000); https://doi.org/10.1053/bega.1999.0065.
  3. C. Sostres, C.J. Gargello, M.T. Arroyo and A. Lanas, Best Pract. Res. Clin. Gastroenterol., 24, 121 (2010); https://doi.org/10.1016/j.bpg.2009.11.005.
  4. S.C. Shih and C.W. Chang, Int. J. Gerontol., 1, 40 (2007); https://doi.org/10.1016/S1873-9598(08)70022-X.
  5. C.I. Neutel and W.C. Appel, Ann. Epidemiol., 10, 246 (2000); https://doi.org/10.1016/S1047-2797(00)00040-5.
  6. R.N. Gursoy and S. Benita, Biomed. Pharmacother., 58, 173 (2004); https://doi.org/10.1016/j.biopha.2004.02.001.
  7. R. Challa, A. Ahuja, J. Ali and R.K. Khar, AAPS PharmSciTech, 6, E329 (2005); https://doi.org/10.1208/pt060243.
  8. H. Bera, S. Chekuri, S. Sarkar, S. Kumar, N.B. Muvva, S. Mothe and J. Nadimpalli, J. Mol. Liq., 215, 135 (2016); https://doi.org/10.1016/j.molliq.2015.12.054.
  9. I.A. Alsarra, M.O. Ahmed, F.K. Alanazi, K.E.H. Eltahir, A.M. Alsheikh and S.H. Neu, Int. J. Med. Sci., 7, 232 (2010); https://doi.org/10.7150/ijms.7.232.
  10. J. Barbosa, A. Zoppi, M. Quevedo, P. de Melo, A. de Medeiros, L. Streck, A. de Oliveira, M. Fernandes-Pedrosa, M. Longhi and A. da Silva-Júnior, Int. J. Mol. Sci., 15, 17077 (2014); https://doi.org/10.3390/ijms150917077.
  11. F. Sami, B. Philip and K. Pathak, AAPS PharmSciTech, 11, 27 (2010); https://doi.org/10.1208/s12249-009-9350-y.
  12. M.M. Maitre, M.R. Longhi and G.G. Granero, Drug Dev. Ind. Pharm., 33, 311 (2007); https://doi.org/10.1080/03639040600901978.
  13. E. Redenti, L. Szente and J. Szejtli, J. Pharm. Sci., 90, 979 (2001); https://doi.org/10.1002/jps.1050.
  14. H.S. Gwak, J.S. Choi and H.K. Choi, Int. J. Pharm., 297, 156 (2005); https://doi.org/10.1016/j.ijpharm.2005.03.016.
  15. H.K. Han and H.K. Choi, Eur. J. Pharm. Biopharm., 65, 99 (2007); https://doi.org/10.1016/j.ejpb.2006.07.003.
  16. N. Rouge, P. Buri and E. Doelker, Int. J. Pharm., 136, 117 (1996); https://doi.org/10.1016/0378-5173(96)85200-8.
  17. A.H. El-Kamel, M.S. Sokar, S.S. Al-Gamal and V.F. Naggar, Int. J. Pharm., 220, 13 (2001); https://doi.org/10.1016/S0378-5173(01)00574-9.
  18. S. Miyazaki, N. Kawasaki, W. Kubo, K. Endo and D. Attwood, Int. J. Pharm., 220, 161 (2001); https://doi.org/10.1016/S0378-5173(01)00669-X.
  19. W. Kubo, S. Miyazaki and D. Attwood, Int. J. Pharm., 258, 55 (2003); https://doi.org/10.1016/S0378-5173(03)00163-7.
  20. M. Prabaharan and J.F. Mano, Macromol. Biosci., 6, 991 (2006); https://doi.org/10.1002/mabi.200600164.
  21. P.S. Rajinikanth J. Balasubramaniam and B. Mishra, Int. J. Pharm., 335, 114 (2007); https://doi.org/10.1016/j.ijpharm.2006.11.008.
  22. B.C. Thanoo, M.C. Sunny and A. Jayakrishnan, J. Pharm. Pharmacol., 45, 21 (1993); https://doi.org/10.1111/j.2042-7158.1993.tb03672.x.
  23. M.H. Dehghan and M. Jafar, Iran. J. Pharm. Res., 4, 231 (2006).
  24. M. Jafar, M.H.G. Dehghan and A. Sharif, Int. J. Appl. Pharm., 2, 22 (2010).
  25. A. Aejaz, M. Jafar, M.H.G. Dehghan and A. Shareef, Int. J. Pharm. Pharm. Sci., 2, 182 (2010).
  26. O. Radia, E. Rogalska and G. Moulay-Hassane, Pharm. Dev. Technol., 17, 632 (2012); https://doi.org/10.3109/10837450.2011.565347.
  27. H. El-Maradny, S.A. Mortada, O. Kamel and A. Hikal, Acta Pharm., 58, 455 (2008); https://doi.org/10.2478/v10007-008-0029-9.
  28. W. Samprasit, P. Akkaramongkolporn, T. Ngawhirunpat, T. Rojanarata, P. Opanasopit, Drug. Dev. Ind. Pharm., 41, 1006 (2015); https://doi.org/10.3109/03639045.2014.922573.
  29. S.S. Awasthi, T.G. Kumar, P. Manisha, Y. Preeti and S.S. Kumar, Pak. J. Pharm. Sci., 24, 533 (2011).
  30. K. Gowthamarajan, T.G. Kulkarni, G. Venkateswaran, M.K. Samanta and B. Suresh, Indian J. Pharm. Sci., 64, 525 (2002).
  31. M. Jafar and S. Ali, Int. Res. J. Pharm., 2, 220 (2011).
  32. G.E.P. Box and K.B. Wilson, J. Royal Statist. Soc., Ser. B, 13, 1 (1951).
  33. S. Alam, M. Aslam, A. Khan, S.S. Imam, M. Aqil, Y. Sultana and A. Ali, Drug Deliv., 23, 601 (2016); https://doi.org/10.3109/10717544.2014.923958.
  34. T. Higuchi and K.A. Connors, Adv. Anal. Chem. Instrum., 4, 117 (1965).
  35. D. Wang, H. Li, J. Gu, T. Guo, S. Yang, Z. Guo, X. Zhang, W. Zhu and J. Zhang, J. Pharm. Biomed. Anal., 83, 141 (2013); https://doi.org/10.1016/j.jpba.2013.05.001.
  36. K.M. Lokamatha, A. Bharati, S.M.S. Kumar and N.R. Rao, Int. J. Pharm. Pharm. Sci., 2, 169 (2010).
  37. A.A. Jamdhade, R.S. Shendge and V. V. Pande, Int. J. Drug Deliv., 6, 230 (2014).
  38. A. Sharma, J. Sharma, R. Kaur and V. Saini, BioMed. Res. Int., Article ID 876182 (2014); https://doi.org/10.1155/2014/876182.
  39. P.S. Rajinikanth and B. Mishra, Chem. Pharm. Bull. (Tokyo), 57, 1068 (2009); https://doi.org/10.1248/cpb.57.1068.
  40. C.A. Winter, E.A. Risley and R.H. Silber, J. Pharmacol. Exp. Ther., 162, 196 (1968).
  41. P. Pandya, N.K. Pandey, S.K. Singh and M. Kumar, J. Appl. Pharm. Sci., 5, 88 (2015); https://doi.org/10.7324/JAPS.2015.50615.
  42. P. Costa and J.M. Sousa Lobo, Eur. J. Pharm Sci., 13, 123 (2001); https://doi.org/10.1016/S0928-0987(01)00095-1.
Read More
Author biographies is not available.
Download
PDF
Statistic
Read Counter : 0 Download : 0